

# CGTP SUMMIT 2024



## KNOWLEDGE SHARING AND CAPACITY BUILDING

- Comparability has *continuously emerged as a recurring and inevitable hurdle* due to the poorly understood and characterized nature of CGT products.
- Cell-based medicinal products have proven to be *difficult to characterize and standardize* with currently available analytical methodologies.
- Off-the-shelf products manufacturable in relatively large quantities could *significantly increase access for patients while reducing the cost of manufacturing* for companies.
- Comparability assurance – it doesn't stop. *Continuous monitoring is necessary.*

## CGTP Summit 2024 **BY THE NUMBERS**



**First-Time Attendees**

**53**



**Regulators Participated**

**26**



**Companies Represented**

**83**



**Countries Collaborated**

**15**

Canada | China | Denmark | Finland | France | Germany | Ireland | Japan | Netherlands | Portugal | Saudi Arabia | Spain | Sweden | United Kingdom | United States

